Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$0.55
>-$0.01(-0.08%)
At close: 4:00 PM EDT
$0.55
>-$0.01(-0.08%)
Day’s Range― - ―
52-Week Range$0.08 - $1.69
Previous Close$0.47
Volume28.41K
Average Volume (3M)3.27M
Market Cap
$2.72M
Enterprise Value$32.73M
Total Cash (Recent Filing)$7.74M
Total Debt (Recent Filing)$26.00M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding27,439,327
10 Day Avg. Volume3,798,837
30 Day Avg. Volume3,270,445
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap12.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-367.79
Enterprise Value/Ebitda-1.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressMeaningful clinical execution and a completed pivotal trial could support regulatory approval and future commercialization of the vCLAS system. The reported patient experience, trial completion speed, and expected FDA decision create identifiable milestones that may strengthen the company’s competitive position if results translate into approval.
Debt Reduction Through ConversionConverting part of the senior secured notes into equity can reduce principal obligations and future interest pressure during the strategic review. Although dilution affects existing holders, a lower debt burden could improve financial flexibility and make the capital structure easier to manage over the coming quarters.
Improving Loss And Cash TrendsThe improvement in losses and cash outflows indicates some cost control or reduced spending, which could extend operating capacity relative to earlier periods. This is not yet profitability, but a less negative trajectory may help management preserve resources while pursuing regulatory and commercialization milestones.
Bears Say
No Commercial RevenueThe absence of reported revenue shows that the company has not yet reached a scalable commercial stage, leaving its business model dependent on successful development and eventual adoption of its devices. Persistent net and gross losses also reduce evidence that future sales can support operating costs.
Persistent Cash BurnSubstantial negative operating and free cash flow means the business is not funding itself internally and likely requires external capital or strategic action. Continued cash consumption can limit investment in development and commercialization while increasing dependence on financing conditions and management’s ability to control spending.
Negative Equity And Restructuring RiskNegative equity signals a weakened capital base, while a workforce reduction of more than half of full-time employees may constrain execution across development and commercialization activities. The strategic alternatives process also indicates that the company is addressing significant financial pressure rather than operating from a position of stability.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.08 and its highest was $1.69 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $2.72M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 24 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on Aug 11, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.03.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Overvalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.25.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 27,439,327 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -3.36%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Technical Analysis
Ownership Overview
36.85% Insiders
0.38% Mutual Funds
53.55% Other Institutional Investors
8.82% Public Companies and
Individual Investors